Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tryptamine Therapeutics ( (AU:TYP) ) has shared an update.
Tryptamine Therapeutics has initiated a world-first clinical trial in collaboration with Swinburne University to assess the safety and efficacy of TRP-8803 for treating Binge Eating Disorder (BED). This trial, which involves 12 patients, aims to explore the potential of TRP-8803 in reducing binge-eating episodes and addressing associated psychiatric comorbidities. The company has also strengthened its board by appointing Mr. Herwig Janssen, a seasoned pharmaceutical executive, as Chairman, which is expected to enhance its strategic direction and industry positioning.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited is a clinical-stage biotechnology company based in Melbourne, Australia. The company focuses on developing psychedelic compounds for therapeutic purposes, with a particular emphasis on treating mental health disorders. Their primary product, TRP-8803, is an IV-infused psilocin used in conjunction with psychotherapy to address conditions such as Binge Eating Disorder (BED).
Average Trading Volume: 1,638,565
Technical Sentiment Signal: Sell
Current Market Cap: A$44.61M
Find detailed analytics on TYP stock on TipRanks’ Stock Analysis page.